Evgen Pharma Share Discussion Threads

[njb67] 22/1/2021 20:23

mm

do not troll me. filtered.

[moneymunch] 22/1/2021 20:19

So do I mate...Evgen is a virtual Biotech who's business model is to seek non-dilutive funding to advance their pipeline towards commercial JV partnership...they probably don't even employ a window cleaner let alone a labrotary full of scientists...they have enough cash for their stated business model until end of this year...so what's your beef????

[njb67] 22/1/2021 20:16

mm 628

Which bit of my post 625 do you not understand?

"I have followed this thread and have been looking at EVG for a number of months before buying shares yesterday. I plan to hold these until the company prospects are fully recognised in the share price (many multiples of the price today) or if the story changes and I do not believe the share is no longer significantly undervalued."

I would sell out if I believed the share price was no longer significantly undervalued. I bought shares yesterday because I believe the company is significantly undervalued.
I still hold those shares because my view has not changed, the company is significantly undervalued.

If you are going to misrepresent my posts, then I will not waste my time engaging with you.

[lovewinshatelosses] 22/1/2021 20:16

Well, I cannot be the only person who was not surprised to see a red day today, in spite of yet another good RNS.
The subject of fundraising keeps coming up. From my perspective, if it is going to happen, I am open-minded to it, as long as the BOD buy in heavily from their own pocket and the objectives are clearly outlined. Ideally at a premium and certainly not at an AIM special heavy discount.
Stig mentioned earlier about a fear of some PI's to a fund raise. I do not believe that most PI's who invest in small caps like these have anything of the sort. We just do not like to stump up cash when those on the payroll do not do similarly. Or indeed like some AIM outfits that dilute the living daylights out of existing holders, as MSYS seem to have, for example.
I feel a degree of comfort with some of the people who are invested here. I do not understand why we are where we are as a company right now, but I guess as long as the news keeps rolling, eventually we will start to attract some bigger investors and that will hopefully have a snowball effect on the share price Anyway, have a good weekend all and lets see where next week brings us.

[euclid5] 22/1/2021 20:15

was that a 1m sell today at 11.125p, so that may of stopped the rise

[nobbygnome] 22/1/2021 19:49

>> MM

You really don't have a clue. The company is undervalued whether they need a fund raising or not. If you put your head in the sand about the possibility of a fund raising you are being extremely naive. You have to go into investments with your eyes fully open as to what the possibilities are both negative and positive.

Yes I think the chances of the drug working in pneumonia are slim but the cancer indications are all extremely promising. I also like the Juvanescence collaboration. I expect a strong rise ahead of the Covid results but I will be completely upfront and will sell the majority before those results come out. At some point I will explain precisely why I don't think it will work in pneumonia from a scientific point of view......but that is for another time.

The bottom line is I go into investments with my eyes fully open and not being completely unrealistic about the expectations.

[moneymunch] 22/1/2021 19:46

Strange time to take a position when he spends his time bleating on about a placing, as it would appear a certain band of cohorts are happy to do...and I'm the one accused of dumping my shares and driving down the share price ..you couldn't make it UP!!! :-(


Nobbygnome - 22 Jan 2021 - 05:23:05 - 6555 of 6629

Evgen Pharma: Developing Sulforaphane to treat Stroke, MS and Cancer - EVG

BTW it's good to see njb67 take a position here. He is another Pharma chap who actually knows what he is talking about!

[moneymunch] 22/1/2021 19:36

Lol....hang on a minute njb67, Nobbyghome hasn't stopped for days proclaiming how ridiculous the share price and market value is undervalued, he literally hasn't stopped, yet you arrive and proclaim the following after the share price ended in the red....who needs comedy on a friday night on TV....ha ha ho ho...:')

" and I do not believe the share is no longer significantly undervalued."

[nobbygnome] 22/1/2021 19:24

>> njb

If you have followed the thread for a while you will know that you will only get overexuberant optimism with unrealistic expectations from MM. Is it so good to see some more rational contributions here! Of course a fund raising will happen at some point. Yes they may be able to delay it but as sure as night follows day, another fund raising will come around.

[njb67] 22/1/2021 19:14

mm

If that is directed at me, then no. I invest in companies that I think are substantially undervalued and then wait until the market catches up. Old fashioned value investment approach.

I have followed this thread and have been looking at EVG for a number of months before buying shares yesterday. I plan to hold these until the company prospects are fully recognised in the share price (many multiples of the price today) or if the story changes and I do not believe the share is no longer significantly undervalued. I have neither the time, ability nor temperament to second guess short term share price movements. I am looking to buy pound coins for pennies rather than scalp a few percentage points here and there.

[moneymunch] 22/1/2021 19:05

Lol...do you also trade on Spreadex by any chance...if Evgen raise cash then it will be for an exceptional material event imho as it is totally the opposite to their business model, especially when the CEO has recently stated that they have enough cash until end of year...Bring it on!!! :-)

[njb67] 22/1/2021 19:00

mm

This is a small cap pharma with no revenue. At some point it will need to raise monies, it is inevitable. Unless some kind person gifts EVG the cash, then there will be dilution of existing shareholders. It is how this sector works.

I do find the EVG use of "non-dilutive" unhelpful. While the intention may well be to enter an agreement that does not negatively impact the share price, they will be giving away a claim on the future revenues of the company in return for investment. Today shareholders own 100% of the future revenues of the pipeline. By giving away some of these revenues in return for investment, shareholders have been diluted.

On timing, no sensible company will wait until their cash is about to run out before tapping the market, that would be irresponsible. I would expect a fund raise Q2-3, or should the share price rise substantially in the near term, so you are giving away less of the prospects of the business.

As others have mentioned, a fund raise that sped the development of pipeline assets should net net be the most effective way to create shareholder value through the early commercialisation or sale of the assets.

[moneymunch] 22/1/2021 18:34

A little reminder of the business model, also that the CEO stated last month that they had enough cash until end of year....which suggests that no placing is likely at the moment. Gla ;-)

Our strategy is to move to a business model where we facilitate multiple clinical trials on SFX-01 in risk-sharing arrangements, with the objective of attracting non-dilutive funding from grants and/or charities to wholly or substantially fund future clinical activity. This strategy has three key components:

(1) Our first priority is to ensure the continued development of the breast cancer programme. We will complete the trial design and cost a clinical trial protocol and then seek non-dilutive funding for Evgen and/or an affiliated clinical institution to sponsor the trial.

(2) In parallel we aim to leverage the extensive pre-clinical and clinical data that shows the potential for SFX-01, as a sulforaphane delivery platform, to be used in diseases that are beyond our capacity to pursue.

(3) In addition, we will pursue opportunities to apply our intellectual property on stabilised sulforaphane to non-pharmaceutical opportunities which offer a more rapid route to market.

We will therefore support a number of proposed Investigator-Initiated Trials - these are trials led by a clinician from a well-renowned institution, with that institution being the sponsor for the trial. Evgen will provide support as required (in the confines of an investigator sponsored study), sharing our knowledge, experience and the methods and laboratories used for pharmacodynamic and pharmacokinetic endpoints. All such trials are subject to grant funding being procured and Evgen will supply clinical centres with SFX-01 and, where appropriate, a placebo.

Evgen will have the right to access the clinical data on fair commercial terms to advance its clinical and commercial development. Since the principal funding for these trials will be obtained by the investigator/ institution they have limited impact on our cash reserves.

[rickus] 22/1/2021 17:33

OK
Bad wording
Substitute pre-clinical work for where I have wrongly said trials.

[on target] 22/1/2021 17:23

What trials are you referring to rickus?

[rickus] 22/1/2021 17:20

Will try this again, now things are a bit quieter...

Would someone be kind enough please to give me a better understanding of pre-clinical data.

I assume that the trials can vary quite considerably - even the spelling of pre-clinical varied in the two recent announcements!

Are there any specific criteria that have to be applied to the trials other than that they do not involve testing on humans?

Will the company have specified trial protocols and end points? e.g.
Do we have more information on the nature of these trials?
Would the data to underpin the last two releases have been specifically targeted or is it more likely that they released the information as soon as they uncovered some meaningful evidence?

What is the context of these two trials - i.e. what is it reasonable to assume would follow on?

Do these two trials in any way compliment each other or any of the other work being undertaken by the company?

[on target] 22/1/2021 17:17

1M sell just printed from this morning, which explains where the supply was coming from this afternoon. Anyone on here?

[nobbygnome] 22/1/2021 16:26

>> MM

I ask the question of my account handler. They are very open with the information. Indeed IG you can see it on the APP in all shares. And yes occasionally I go short on companies but it would be less than 5% of my total trades

[someuwin] 22/1/2021 16:22

Bought more.

[moneymunch] 22/1/2021 15:18

Obviously, punters go short from time to time, when they can. :-)

Nobbygnome - 01 Nov 2020 - 15:29:16 - 5035 of 6614

Evgen Pharma: Developing Sulforaphane to treat Stroke, MS and Cancer - EVG

And just to add quite often Spreadex won't let you short small companies. I haven't tried with EVG but on several occasions recently I haven't been able to with other companies.

[moneymunch] 22/1/2021 15:01

I'm surprised you know the status of Spreadex customers, and are transactions there of benefit to daily performance here?

[nobbygnome] 22/1/2021 14:47

On the vast majority of stocks most people are long not short. I happen to know the short position on OPTI is zero. So as usual you are talking nonsense....

[moneymunch] 22/1/2021 14:44

Yes you can go long but the trades aren't registered here on execution and so make no difference to volume, and Spreadex is essentially a shorting platform...which I'm sure you're well aware.